Skip to content
Sign in

ABUS · NASDAQ

Arbutus Biopharma (ABUS) Stock Price & Fundamentals

$397.17+0.13%+$0.51End-of-day price as of Oct 9, 2026

Arbutus Biopharma (ABUS) closed at $397.17 on Oct 9, 2026, up 0.13% from the previous close of $396.66.

Share price, past year

1Y +1.66%

52-week range $376.61 – $436.89. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$397.17
Sep 30, 2026$412.34
Aug 31, 2026$414.08
Jul 31, 2026$392.77
Jun 30, 2026$399.49
May 29, 2026$389.69
Apr 30, 2026$393.80
Mar 31, 2026$408.15
Feb 27, 2026$397.38
Jan 30, 2026$424.00
Dec 31, 2025$413.16
Nov 28, 2025$423.58
Oct 31, 2025$381.47

Key statistics

Market cap
$78.49B
P/E (TTM)
490.3
EPS (TTM)
$0.81
Revenue (TTM)
$181.72M
Net income (TTM)
$153.05M
Shares outstanding
197.6M
Dividend yield
—
52-week range
$376.61 – $436.89

Arbutus Biopharma's market cap is $78.49B, based on a share price of $397.17 and 197.6M shares outstanding as of Jun 30, 2026.

Financials

Arbutus Biopharma reported revenue of $14.08M for fiscal 2025, up 128.21% from fiscal 2024.

Arbutus Biopharma reported a net loss of $33.50M in fiscal 2025.

Annual revenue

FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Annual revenue by fiscal year; the table below lists the values.
Arbutus Biopharma annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2025ended Dec 31, 2025$14.08M+128.2%−$33.50M−237.9%−$0.17−$39.64M
FY2024ended Dec 31, 2024$6.17M−66.0%−$69.92M−1,133.0%−$0.38−$65.03M
FY2023ended Dec 31, 2023$18.14M−53.5%−$72.85M−401.6%−$0.44−$86.94M
FY2022ended Dec 31, 2022$39.02M+255.1%−$69.46M−178.0%−$0.46−$35.87M
FY2021ended Dec 31, 2021$10.99M+58.9%−$76.25M−693.9%−$0.83−$68.34M
FY2020ended Dec 31, 2020$6.91M+15.0%−$63.75M−922.0%−$1.00−$51.67M
FY2019ended Dec 31, 2019$6.01M+1.1%−$153.72M−2,557.4%—−$71.60M
FY2018ended Dec 31, 2018$5.95M−44.4%−$57.06M−959.8%−$1.21−$69.00M
FY2017ended Dec 31, 2017$10.70M+617.6%−$84.41M−788.9%−$1.56−$55.90M
FY2016ended Dec 31, 2016$1.49M—−$384.16M−25,765.5%−$7.24−$61.88M
Arbutus Biopharma quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q2 FY2026ended Jun 30, 2026$1.01M−$5.14M−$0.03
Q1 FY2026ended Mar 31, 2026$179.13M$169.70M$0.87
Q4 FY2025ended Dec 31, 2025$1.05M−$3.76M—
Q3 FY2025ended Sep 30, 2025$529.00K−$7.74M−$0.04
Q2 FY2025ended Jun 30, 2025$10.74M$2.52M$0.01
Q1 FY2025ended Mar 31, 2025$1.76M−$24.53M−$0.13
Q4 FY2024ended Dec 31, 2024$1.57M−$12.53M—
Q3 FY2024ended Sep 30, 2024$1.34M−$19.72M−$0.10

Company profile

Name
Arbutus Biopharma Corp
Ticker
ABUS
Exchange
NASDAQ
Industry (SEC SIC)
Pharmaceutical Preparations
Headquarters
701 Veterans Circle, Warminster, PA 18974
Incorporated in
A1
Fiscal year ends
December
SEC CIK
0001447028

Recent SEC filings

Frequently asked questions

What is Arbutus Biopharma's stock price?

Arbutus Biopharma (ABUS) closed at $397.17 on Oct 9, 2026, up 0.13% from the previous close of $396.66.

What is Arbutus Biopharma's market cap?

Arbutus Biopharma's market cap is $78.49B, based on a share price of $397.17 and 197.6M shares outstanding as of Jun 30, 2026.

How much revenue does Arbutus Biopharma make?

Arbutus Biopharma reported revenue of $14.08M for fiscal 2025, up 128.21% from fiscal 2024.

What is ABUS's P/E ratio?

Arbutus Biopharma's price-to-earnings ratio is 490.3, based on trailing twelve-month diluted EPS of $0.81.

Does Arbutus Biopharma pay a dividend?

Arbutus Biopharma's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from Arbutus Biopharma Corp's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 8, 2026. Data sources and disclosures